我就言简意赅的表达一下HerpV的状况：该疫苗是治疗型疫苗，专门针对HSV2的生殖器疱疹病毒，第一阶段在试验诊所的所有志愿者都有效，该疫苗主要是和QS-21结合的治疗技术，QS-21好像是热蛋白，该疫苗激发我们的免疫系统产生抗体，专业角度来讲该抗体就是指让免疫系统产生T细胞。再具体一点HerpV让人体免疫系统产生CD4+和CD8+两种T细胞抗体。再看了下HperV官网描述的进展如下：
The results of the study, published in
Vaccine, show that HerpV administered with QS21 adjuvant was associated with a significant induction of both CD4+ in 7/7 subjects (100%) and CD8+ in 6/8 subjects (75%) cellular immune response.
以上意思是用了HerpV的患者中100%的患者体内有CD4+抗体，而75%的患者体内有CD8+抗体。现在我比较纠结这个25%的没有CD8+抗体的患者是否能100%消灭病毒。所以该公司在2012年进行了第二阶段的HerpV疫苗试验，主要是统计HerpV的减毒效果，我想年底应该会有结果了。到时候我会在这里告诉大家结果，希望这是大家的救星。
如果结果不错，我甚至考虑第一时间把这个疫苗代理到中国来，从该公司的CEO来看要商用至少要到2013年底或2014年了，不知道有多少论坛的朋友想第一时间使用该疫苗来治好你们的疱疹呢？可以留一个email给我，看看有没有必要做这件有意义的事情。。。。
另外这里还有一些其他方面的对于HSV2的好的信息，就不做翻译了，英文好的可以看看（第12项就是预计2019年面世的
Genocea公司的治疗性疫苗计划，貌似太遥远了）：
http://www.hsvblog.org/herpes-hsv-research-for-a-cure/主要讲目前对于HSV2的药物进展和其他疫苗进展，说不定有更好的疫苗诞生了，上面还有做爱时防止传染的药物等等。。。都是好消息。
发这个帖子主要是因为看到很多论坛的朋友觉得自己感染了HSV2就像世界莫日降临似的，所以为了增加大家的信心和希望，我特地发了此贴，希望所有论坛朋友都能看到这个好消息，然后开心地学习、生活和工作，不要让疱疹左右你的情绪，养好自己的身体，好好等待希望和救星的到来！Herpes Therapeutic Vaccine 2012March 16, 2012 Posted by Carson
In an electrifying bit of news in the fight against herpes, one of the globe's foremost research firms just revealed that it might be closing in on producing a vaccine for the HSV-2 virus that causes the infection. U.S. biotechnology manufacturer Agenus Inc. introduced results from its continuing research last month indicating that its developmental product, HerpV, successfully prevented the appearance of
genital herpes symptoms in men and women who participated. Even more impressively, the pharmaceutical also seemed to block the virus' ability to infect a new person.
What Makes HerpV Workc
Without diving too far into complex biology, HerpV functions by stimulating an immune mechanism reaction that enhances cells' capacity to identify the
herpes virus. This is achieved by injecting what is known as a "heat shock protein", or HSP, into the bloodstream. Once in the system, the HSP attaches itself onto the exterior of healthy blood cells, consequently leading infected blood cells to become incompatible and unable to attach themselves (i.e., duplicate).
By preventing the genital herpes virus from replicating, HerpV effectively renders it incapable of triggering outbreaks in current patients and non-infectious to herpes-negative people. This is certainly an exhilarating proposition for the approximated 16% of the population now struggling with genital herpes.
How Notable Are Agenus' Discoveriesc
In what was referred to as a Phase 1 study, 100% of herpes-infected patients who were given a HerpV injection exhibited a major elevation in antigen-targeted cell immune mechanism response to the virus. In common terminology, this indicates that the T cells in every one of the study's subjects became immune to HSV-2 soon after being exposed to the HSP.
Dr. David Koelle, a medical professor for the University of Washington School of Medicine, delivered the findings on behalf of Agenus and gave the ensuing statement, "I believe these data represent the first finding of their kind in humans in
genital herpes treatments." The professor continued on to declare, "The potential use for a therapeutic vaccine candidate such as HerpV is in managing outbreaks and ultimately disease transmission in patients with genital herpes."
Does This Mean That A Vaccine Is Coming Soonc
The ramifications of these preliminary results on HerpV are tremendous. Dr. Koelle reinforced this point thusly, "Being able to impact and possibly decrease the spread of genital herpes would be a huge step in stemming this epidemic that affects one in six adults in the U.S." With all of the excitement that this announcement generated, a logical question was "So, how close is the HerpV vaccine to being released to the publicc"
Although it might not be too far off, it is unlikely that the vaccine will be made available to existing genital herpes patients at any time in the immediate future. Agenus is just now beginning Phase 2 of its research on the drug's effectiveness and, as long as it proves successful, would then be required to submit to the FDA-approval program before launching the vaccine. Given that this process can sometimes take years, the fight to eliminate herpes symptoms in men and women might not be as near to its conclusion as we would like to believe.
